We use some necessary cookies to make this website work properly.
We want to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other websites to help us provide content from their services.
You can change your cookie settings at any time.
Search the department to understand what the government is doing
Departments, institutions and public institutions
News reports, speeches, letters and announcements
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Free release of data, information and company reports
The government signs a contract to purchase a total of 114 million additional doses of Pfizer/BioNTech and Moderna in 2022 and 2023
The government has signed a new contract to ensure the supply of our vaccine stocks to prove the future of the country’s vaccine program.
In light of the new variants, the new contracts with Pfizer/BioNTech and Moderna have been accelerated as part of an ongoing effort to ensure that the government does what it can, while scientists around the world learn more about Omicron. These future supply deals include access to improved vaccines, if they are needed to counter Omicron and future variants of attention, and be prepared for everything that might happen.
The agreement signed through the Vaccine Working Group builds on existing partnerships with vaccine companies. The government will purchase an additional 114 million doses of Pfizer/BioNTech and Moderna vaccines in 2022 and 2023. This is an additional order of 1 million doses of Pfizer/BioNTech in August 35, which will be delivered in the second half of next year. It is estimated that there will be 60 million doses of Novavax and 7.5 million doses of GlaxoSmithKline/Sanofi (GSK/Sanofi) in 2022.
After the emergence of the new variant, the Minister of Health and Social Care asked the Joint Committee on Vaccination and Immunization (JCVI) to provide quick advice on extending the strengthening program to all people 18 years of age and older. The recommendation was accepted this week, and an operational plan to accelerate the vaccine program was developed, and vaccines will be provided to all eligible adults in England by the end of January.
To expedite the vaccination plan, approximately 400 military personnel will be recruited to support the deployment, and 1,500 community pharmacies, additional hospital centers, and pop-up sites will be opened in convenient locations across the country. More than 3,000 sites have been opened in England-more than twice the number in February. The government has provided sufficient Moderna and Pfizer/BioNTech supplies for the expanded booster program, and the new agreement ensures that we will continue to have the supplies needed to move forward.
The Minister of Health and Social Care Sajid Javid said:
Thanks to the Vaccine Working Group, we have an excellent track record in obtaining the vaccine that the country needs to stop this virus.
These new deals will prove the great UK vaccination effort in the future — which has so far carried out more than 115 million first, second and booster vaccinations across the UK — and will ensure that we can protect in the coming years more people.
This is a national mission, and our best weapon against this virus and its variants is slam - so when you are called forward, slam and get promoted.
For the enhancement plan, JCVI has recommended Pfizer/BioNTech and Moderna to provide mRNA vaccines.
Data from the COV-BOOST trial shows that booster doses of COVID-19 vaccine are generally well tolerated and significantly increase the immune response induced by the vaccine. In particular, mRNA vaccines provide a powerful boosting effect.
In addition to ensuring that we have supplies to protect the public in this country, the UK is still committed to donating 100 million doses to countries in need by mid-2022. By the end of 2021, we will donate more than 30 million vaccines, and we have announced a donation plan. So far, we have donated a total of 70 million vaccines.
We will continue to work hard to ensure that any vaccine that the UK does not need is redistributed as much as possible to other countries that need it.
The latest data shows why boosters are so important. The latest evidence from the Scientific Advisory Group for Emergency Situations (SAGE) shows that protection against symptomatic diseases from Delta variants has dropped from 65% at most 3 months after the second vaccination to 45% at 6 months after the second vaccination . /AstraZeneca vaccine, and Pfizer/BioNTech vaccine 90% to 65%. The hospitalization protection rate for Oxford/AstraZeneca was reduced from 95% to 75%, and the hospitalization rate for Pfizer/BioNTech was reduced from 99% to 90%.
The first UK real-world study published by the UK Health and Safety Agency in November showed that boosters provide more than 90% protection against symptomatic COVID-19 for adults over 50 years old, which strengthens the booster’s effectiveness. The importance of ensuring people’s safety before winter comes.
The results of these studies show that, two weeks after receiving the booster dose, adults aged 50 and older with Oxford/AstraZeneca as the main course of treatment have a 93.1% protection rate against symptomatic infections, and Pfizer/BioNTech’s protection rate is 94.0%.
Check what you need to do
Do not include personal or financial information, such as your National Insurance number or credit card details.
To help us improve GOV.UK, we would like to learn more about your visit today. We will send you a link to the feedback form. It only takes 2 minutes to fill in. Don't worry, we will not send you spam or share your email address with anyone.